PanEcho isn’t yet ready to be a standalone tool, researchers say, but shows promise at improving workflows and patient care.

The procedures are not mutually exclusive, however, and should be considered on a patient-by-patient basis, a researcher says ...

Labels for the Pfizer and Moderna shots, which already caution about myocarditis and pericarditis, will more strongly stress ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

This month: pharmacy’s growing CICU role, arrhythmias’ impact on pregnancy, Life’s Essential 8 in practice, and more.

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Grant ...

In an early look at SCOT-HEART 2, CCTA led more primary-prevention patients to make changes to reduce their risk of CVD.

Acute MI mortality has fallen, yet deaths from other diseases, including heart failure and hypertension, are on the rise.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

In DETECT AS, the passive notifications improved rates of AVR and boosted survival, with bigger gains in women.